Thalidomide and thalidomide analogues for induction of remission in Crohn's disease

摘要: Background Crohn's disease is a chronic relapsing condition of the alimentary tract with high morbidity secondary to bowel inflammation. High levels tumour necrosis factor-alpha (TNF-α) have been associated development intestinal inflammation in Crohn's disease.Thalidomide, has demonstrated anti TNF-α properties experimental and clinical studies. Objectives To evaluate efficacy safety thalidomide its analogue lenalidomide for induction remission disease. Search methods The Cochrane Central Register Controlled Trials (CENTRAL) Issue 3, 2008, PUBMED (1966 August 2008), EMBASE (1984 2008) IBD/FBD Specialised Trial were searched. Manufacturers leaders field also contacted identify any unpublished trials. Study references searched additional trials. Selection criteria Randomised controlled trials (RCTs) that compared or against placebo other intervention eligible inclusion. Data collection analysis Data extraction assessment methodological quality included studies independently performed by two authors. The main outcome measure was remission. Odds ratios 95% confidence intervals calculated dichotomous outcomes. Main results No published RCTs on found. One RCT paediatric patients progress. using (n = 89) met inclusion criteria review. Three parallel groups 25 mg daily 23) , 5 33) 28) studied. rate both treatment not significantly different from group; versus (OR 0.29; CI 0.05 1.54), 5 1.30; 0.42 4.05). There no statistically significant differences response. Authors' conclusions The results one well designed study did show benefit over placebo. use recommended until data definitive are available.